Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Osteoprotegerin Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:OPG, Osteoclastogenesis inhibitory factor, OCIF, TNFRSF11B, Tumor Necrosis Factor Receptor Superfamily Member 11B
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

RD194003200 96 wells (1 kit)
PubMed Product Details
Technical Data


Sandwich ELISA, Biotin-labelled antibody


Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate

Sample Requirements

35 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

1.5–60 pmol/l

Limit of Detection

0.03 pmol/l

Intra-assay (Within-Run)

n = 8; CV = 3.5%

Inter-assay (Run-to-Run)

n = 3; CV = 5.8%

Spiking Recovery


Dilutation Linearity



  • bovine Non-detectable
  • cat Non-detectable
  • dog Non-detectable
  • goat Non-detectable
  • hamster Non-detectable
  • horse Non-detectable
  • mouse Non-detectable
  • pig Non-detectable
  • rabbit Non-detectable
  • rat Non-detectable
  • sheep Non-detectable
  • chicken Not tested
  • human Yes
  • monkey Yes (recommended dilution 1:3)


  • European Union: for in vitro diagnostic use
  • Rest of the world: for research use only!
  • The total assay time is less than 3.5 hours
  • The kit measures osteoprotegerin in serum and plasma (EDTA, citrate, heparin)
  • Assay format is 96 wells
  • Quality Controls are human serum based
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Bone and cartilage metabolism


Osteoprotegerin (OPG, osteoclastogenesis inhibitory factor, OCIF) is a product of
the TNFRSF11B gene, located on chromosome 8q24. OPG belongs to the TNF (tumor
necrosis factor receptor) superfamily, that plays a key role in bone remodeling. Human OPG
is a secreted glycoprotein composed of 401 aminoacid residues. OPG exists as a disulfidelinked
homodimer (120 kDa) or as a monomer (60 kDa). Both of these forms are active but
the dimer is more bioactive than the monomer. In contrast to most members of the TNF
receptor superfamily, OPG probably exists only in a soluble form. Its ligands are RANKL and
TRAIL. Human OPG shares 85% aminoacid identity to mouse OPG and 86 % identity to rat
OPG. In adult humans OPG mRNA is highly expressed in bones (osteblasts), endothelial
vessel cells, skin, liver, stomach, intestine, heart, brain and lung and is also present
in atherosclerotic plaques.

OPG and RANKL are involved in bone resorption and bone formation. OPG and receptor
RANK compete with each other for binding to the ligand RANKL. Binding of RANKL to RANK
stimulates osteoclasts and their activity. When RANKL binds to OPG, osteoclastogenesis
decreases. OPG prevents the formation of RANKL/RANK, inhibits formation of osteoclasts
and suppress bone resorption.

At normal physiological conditions OPG and ligand RANKL are in balance and bone resorption
and bone formation are linked. This balance can be disrupted by the lack of estrogens
in menopausal women, by anti-inflammatory effect of cytokines and by changes in the level
of glucocorticoids, thyroid hormones, parathyroid hormone or calcitriol. Any modification
in the RANKL/OPG ratio can induce either excessive bone resorption or, in contrast, excessive
bone formation. This disregulation can lead to pathological conditions such as
osteoporosis/osteopenia, bone tumor associated osteolysis, or cardiovascular pathology.
In postmenopausal osteoporosis, OPG serum level decreases and this decrease can be
an indicator of a higher risk for bones fracture. In patients with glucocorticoid induced
osteoporosis the RANKL/OPG ratio was higher. In patients with chronic obstructive pulmonary
disease with low bone mineral density (BMD), RANKL/OPG ratio was significantly higher
compared to those with normal BMD.

Patients with juvenile idiopathic arthritis had significantly lower levels of OPG in serum
and lower OPG/RANKL ratio.
The OPG/RANKL/RANK system affects the cardiovascular system as well. In patients with
ischemic heart disease the serum concentration of OPG was higher than that of healthy
people. In patients with high OPG the risk of cardiovascular mortality is three- or four-times
higher than it is in the healthy population.
Finally, the presence of malignant tumors leads to an inhibition of OPG production resulting
in high bone resorption.
The OPG/RANKL/RANK system affects bone loss in many pathological states and participates
in pathogenesis of vascular diseases. Determination of OPG concentration or RANKL/OPG
ratio is a clinical indicator in the diagnosis of the pathological states mentioned below.

Clinical use and areas of investigation:
Postmenopausal and glucocorticoid induced osteoporosis, Reumatoid arthritis, juvenile idiopathic arthritis, Ischemic heart disease, Diseases with changed bone resorption activity

References to Product


  • Abd El Dayem S M, Anwar G M, Salama H, Kamel A F, Emara N. Bone mineral density, bone turnover markers, lean mass, and fat mass in Egyptian children with congenital adrenal, hyperplasia. Arch Med Sci. 2010 Jan;:104-110
  • AbdAllah N, Galal A, Hamed HM, Adolf S, Ragab SH, Abd El Mawgoud S, Rasheed MA. The Roles of Osteoprotegerin and Rankl in Pathogenesis of Osteoporosis in Egyptian Beta Thalassemia Major Patients. Journal of Applied Sciences Re. 2010;6(8): 937-942
  • Abdel-Hameed RE, Badr HW, Abdallah AA, Hanna WM, Salah N. Osteoporosis in diabetic children. Journal of American Science. 2010;6(12)
  • Albu A, Fodor D, Bondor C, Craciun AM. Bone metabolism regulators and arterial stiffness in postmenopausal women. Maturitas. 2013 Oct;76 (2):146-50
  • Avbersek-Luznik I, Balon BP, Rus I, Marc J. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?. Nephrol Dial Transplant. 2005 Mar;20 (3):566-70
  • Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care. 2005 Sep;28 (9):2176-80
  • Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonne JF, Cristol JP, Dupuy AM. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007 Nov;30 (11):2934-9
  • Barbagallo I, Vanella A, Peterson SJ, Kim DH, Tibullo D, Giallongo C, Vanella L, Parrinello N, Palumbo GA, Di Raimondo F, Abraham NG, Asprinio D. Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation. J Bone Miner Metab. 2010 May;28 (3):276-88
  • Bargnoux AS, Dupuy AM, Garrigue V, Deleuze S, Cristol JP, Mourad G. Renal transplantation decreases osteoprotegerin levels. Transplant Proc. 2006 Sep;38 (7):2317-8
  • Boyapati A, Msihid J, Fiore S, van Adelsberg J, Graham NM, Hamilton JD. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Arthritis Res Ther. 2016 Oct 6;18 (1):225
  • Cao H, Wu Y, Li Q, Wu Y, Zhou Q, Røe OD, Chen Y, Wang R, Wang D. Serum sRANKL/OPG predict recurrence after radiofrequency catheter ablation of lone atrial fibrillation. Int J Cardiol. 7 September 2013;
  • Cao H, Zhou Q, Wu Y, Li Q, Roe OD, Chen Y, Wu Z, Wang D. Preoperative Serum Soluble Receptor Activator of Nuclear Factor-kappaB Ligand and Osteoprotegerin Predict Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Valve Surgery. Ann Thorac Surg. 2013 Sep;96 (3):800-6
  • Cao JJ, Johnson LK, Hunt JR. A Diet High in Meat Protein and Potential Renal Acid Load Increases Fractional Calcium Absorption and Urinary Calcium Excretion without Affecting Markers of Bone Resorption or Formation in Postmenopausal Women. J Nutr. 2011 Mar;141 (3):391-7
  • Chae SY, Chung W, Kim YH, et al. The Correlation of Serum Osteoprotegerin with Non-Traditional Cardiovascular Risk Factors and Arterial Stiffness in Patients with Pre-Dialysis Chronic Kidney Disease: Results from the KNOW-CKD Study. J Korean Med Sci. 2018;33(53):e322. Published 2018 Dec 11. doi:10.3346/jkms.2018.33.e322
  • Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT. Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol. 2010 Oct;29 (10):1155-61
  • Clancy P, Oliver L, Jayalath R, Buttner P, Golledge J. Assessment of a serum assay for quantification of abdominal aortic calcification. Arterioscler Thromb Vasc Biol . Nov;26(11):2574-6 (2006)
  • Dai SM, Nishioka K, Yudoh K. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. Ann Rheum Dis. 2004 Nov;63 (11):1379-86
  • di Giuseppe R, ORCID:, Biemann R, Wirth J, Menzel J, Isermann B, Stangl GI, Fritsche A, Boeing H, Schulze MB, Weikert C. Plasma osteoprotegerin, its correlates, and risk of heart failure: a prospective cohort study. Eur J Epidemiol. 2016 Jun 15;
  • Dimitrow PP, Jawień M, Gackowski A. The Influence of Statins on Levels of Calcification Biomarkers in Patients with Aortic Sclerosis or Mild Aortic Stenosis. J Heart Valve Dis. January 2011;20 (1)
  • Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease. Ther Apher Dial. 2009 Feb;13 (1):49-55
  • Dundar U, Kavuncu V, Ciftci IH, Evcik D, Solak O, Cakir T. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study. J Bone Miner Metab. 2009;27 (4):464-70
  • El-Shehaby A, Darweesh H, El-Khatib M, Momtaz M, Marzouk S, El-Shaarawy N, Emad Y. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol. 2011 Oct;31 (5):848-56
  • ElBaky AA, Ismail N, Salama E, Abou-Zekri M, Fatouh A, Ragab S. Inappropriate restriction of dietary gluten and associated bone acquisition and bone density in Egyptian children with coeliac disease. Arch Med Sci. 2009; 5, 4;:589-595
  • Esen H, Büyükyazı G, Ulman C, Taneli F, Arı Z, Gözlükaya F, Tıkız H. Do Walking Programs Affect C-Reactive Protein, Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-Kappaβ Ligand?. Turkish Journal of Biochemistr. 2009; 34 (3) ; 178–186.;
  • Ford ML, Smith ER, Tomlinson LA, Chatterjee PK, Rajkumar C, Holt SG. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrol Dial Transplant. 2011 Jul 12;
  • Friedmann A, Ozmeric N, Bernimoulin JP, et al. Receptor activator of NF-kappaB ligand (RANKL) and CD 31 expressions in chronic periodontitis patients before and after surgery. Cent Eur J Immunol. 2014;39(4):508-17.
  • Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Santolaria-Fernandez F, De la Vega-Prieto MJ, Milena-Abril A, Sanchez-Perez MJ, Martinez-Riera A, Gomez-Rodriguez Mde L. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcohol. 2006 May-Jun;41 (3):261-6
  • Gogo PB Jr, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL. Osteoprotegerin is not associated with angiographic coronary calcification. J Thromb Thrombolysis. 2006 Dec;22 (3):177-83
  • Golledge J, Jayalath R, Oliver L, Parr A, Schurgers L, Clancy P. Relationship between CT anthropometric measurements, adipokines and abdominal aortic calcification. Atherosclerosis. 2008 Mar;197 (1):428-34
  • Gonzalez-Reimers E, Alvisa-Negrin J, Santolaria-Fernandez F, Ros-Vilamajo R, Martin-Gonzalez MC, Hernandez-Betancor I, Garcia-Valdecasas-Campelo E, Gonzalez-Diaz A. Prognosis of osteopenia in chronic alcoholics. Alcohol. 2010 Nov 3;
  • Gossiel F, Hoyle C, McCloskey EV, Naylor KE, Walsh J, Peel N, Eastell R. The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study. Bone. 2016 Aug 12;
  • Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, Arikan E, Tugrul A. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb Res. 2007;120 (4):511-6
  • Gurban C,Zosin I, Sfrijan F, Cojocaru M, Vermesan H, Vermesan D, Savescu I, Radulov I, Drugarin D, Erdelean V. The OPG/sRANKL Systems and the low bone mineral density in postmenopausal osteoporosis. Acta Endocrinologica. vol. V, no. 1, p. 27-40, 2009;
  • Gurban CV, Drugarin D, Corneanu M, Glaja R, Faur A, Ciacli C. The RANK/sRANKL/OPG System - Marker of bone cells in postmenopausal Osteoporosis. Journal of Experimental Medica. Year XIV · Nr.4/2007 · Pag. 17;
  • Ismail NA, El-Shabrawi M, Fatouh AA, Salama E, Abd El Baky AM, El Ghoroury EA, Thabet EH. Risk of Osteoporosis in children with chronic liver diseases. International Journal of Acade. September, 2010;2 (5)
  • Kandil ME, Mourad A, Hamshary AE, Hussein G, Ahmed A. Evaluation of bone mineral density and bone turnover markers in Egyptian children with juvenile rheumatoid arthritis. Arch Med Sci. 2009; 5, 3: 434-442;
  • Kanzaki H, Chiba M, Sato A, Miyagawa A, Arai K, Nukatsuka S, Mitani H. Cyclical tensile force on periodontal ligament cells inhibits osteoclastogenesis through OPG induction. J Dent Res. 2006 May;85 (5):457-62
  • Kim CS, Bae EH, Ma SK, Han SH, Choi KH, Lee J, Chae DW, Oh KH, Ahn C, Kim SW. Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study. PLoS One. 2016;11 (11):e0166792
  • Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol (Oxf). 2005 Nov;63 (5):594-8
  • Kolahi S, Ghorbanihaghjo A, Alizadeh S, Rashtchizadeh N, Argani H, Khabazzi AR, Hajialilo M, Bahreini E. Fish oil supplementation decreases serum soluble receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in female patients with rheumatoid arthritis. Clin Biochem. 2009 Dec 21;
  • Kolonko A, Chudek J, Szotowska M, Kuczera P, Wiecek A. Cardiovascular Risk Factors and Markers of Atherosclerosis in Stable Kidney Transplant Recipients. Transplant Proc. 2016 Jun;48 (5):1543-50
  • Krela-Kazmierczak I, ORCID:, Kaczmarek-Rys M, Szymczak A, Michalak M, Skrzypczak-Zielinska M, Drweska-Matelska N, Marcinkowska M, Eder P, Lykowska-Szuber L, Wysocka E, Linke K, Slomski R. Bone Metabolism and the c.-223C > T Polymorphism in the 5'UTR Region of the Osteoprotegerin Gene in Patients with Inflammatory Bowel Disease. Calcif Tissue Int. 2016 Sep 17;
  • Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA, Dimopoulou MN, Angelopoulou MK, Pangalis GA. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur J Haematol. 2004 Apr;72 (4):252-8
  • Maimoun L, Couret I, Mariano-Goulart D, Dupuy AM, Micallef JP, Peruchon E, Ohanna F, Cristol JP, Rossi M, Leroux JL. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. Calcif Tissue Int. 2005 Jun;76 (6):404-11
  • Marchelli D, Piodi LP, Corradini C, Parravicini L, Verdoia C, Ulivieri FM. Increased serum OPG in atrophic nonunion shaft fractures. J Orthop Traumatol. 2009 Jun;10 (2):55-8
  • Mencej-Bedrac S, Prezelj J, Kocjan T, Teskac K, Ostanek B, Smelcer M, Marc J. The combinations of polymorphisms in vitamin D receptor, osteoprotegerin and tumour necrosis factor superfamily member 11 genes are associated with bone mineral density. J Mol Endocrinol. 2009 Mar;42 (3):239-47
  • Mora S, Zamproni I, Cafarelli L, Giacomet V, Erba P, Zuccotti G, Vigano A. Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. AIDS. 2007 May 31;21 (9):1129-35
  • Morena M, Bosc JY, Jaussent I, Dupuy AM, Terrier N, Leray-Moragues H, Flavier JL, Maurice F, Delcourt C, Cristol JP, Canaud B. The role of mineral metabolism and inflammation on dialysis vascular access failure. J Vasc Access. 2006 Apr-Jun;7 (2):77-82
  • Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, Maurice F, Delcourt C, Cristol JP, Canaud B, Dupuy AM. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2006 Jan;17 (1):262-70
  • Motovska Z, Vichova T, Tousek P, Dusek L, Widimsky P. Circulating osteoprotegerin and Dickkopf-1 changed significantly after surgical aortic valve replacement but remained without any significant differences after transcatheter aortic valve implantation. Int J Cardiol. 2012 Jul 12;158 (2):300-1
  • Najar M, Fayyad-Kazan H, Faour WH, Badran B, Journe F, Lagneaux L. Breast cancer cells and bone marrow mesenchymal stromal cells: a regulated modulation of the breast tumor in the context of immune response. Inflamm Res. 2016 Oct 25;
  • Nakahara T, Kawai-Kowase K, Matsui H, Sunaga H, Utsugi T, Iso T, Arai M, Tomono S, Kurabayashi M. Fibroblast growth factor 23 inhibits osteoblastic gene expression and induces osteoprotegerin in vascular smooth muscle cells. Atherosclerosis. 2016 Aug 20;253:102-110
  • Naylor KE, Rogers A, Fraser RB, Hall V, Eastell R, Blumsohn A. Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab. 2003 Nov;88 (11):5361-5
  • Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol. 2008 Nov;159 (5):603-8
  • Ochiai M, Nakashima A, Takasugi N, Kiribayashi K, Kawai T, Usui K, Shigemoto K, Hamaguchi N, Kohno N, Yorioka N. Vitamin K alters bone metabolism markers in hemodialysis patients with a low serum parathyroid hormone level. Nephron Clin Pract. 2011;117 (1):c15-9
  • Osteoprotegerin: a valid new marker of bone turnover in post-menopausal osteoporosis?. Ulivieri FM, Piodi LP, Marchelli D, Corradini C, Verdoia C, Gerundini Gherardi P. J Orthopaed Traumatol. (2005) 6:88–90
  • Ozkaya O, Buyan N, Bideci A, Gonen S, Ortac E, Fidan K, Cinaz P, Soylemezoglu O. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis. Nephron Clin Pract. 2007;105 (4):c153-8
  • Öztürk VÖ, Emingil G, Bostanci N, Belibasakis GN. Impact of implant-abutment connection on osteoimmunological and microbiological parameters in short implants: a randomized controlled clinical trial. Clinical Oral Implants Researc. July 2016;
  • Passeri E, Mazzaccaro D, Sansoni V, et al. Effects of 12-months treatment with zoledronate or teriparatide on intima-media thickness of carotid artery in women with postmenopausal osteoporosis: A pilot study. Int J Immunopathol Pharmacol. 2019;33:2058738418822439. Published 2019 Jan 7. doi:10.1177/2058738418822439
  • Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005 Nov;90 (11):6323-31
  • Salah H, Atfy M, Fathy A, Atfy M, Mansor H, Saeed J. The clinical significance of OPG/sRANKL ratio in thalassemia patients suffering from osteopenia or osteoporosis in Egyptian patients. Immunol Invest. 2010;39 (8):820-32
  • Salama HM, El-Dayem SA, Yousef H, Fawzy A, Abou-Ismail L, El-lebedy D. The effects of L-thyroxin replacement therapy on bone minerals and body composition in hypothyroid children. Arch Med Sci. 2010; 6, 3: 407-413;
  • Shaarawy M, Fathy SA, Mehany NL, Hindy OW. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure. Clin Chem Lab Med. 2007;45 (11):1498-503
  • Shaker OG, El-Shehaby A, Nabih M. Possible role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as markers of plaque instability in coronary artery disease. Angiology. 2010 Nov;61 (8):756-62
  • Shargorodsky M, Boaz M, Luckish A, Matas Z, Gavish D, Mashavi M. Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women. Atherosclerosis. 2008 Oct 31;
  • Shin MJ, Kim BS, Kim YO, Song HC, Kim Yo, Kim SY, Choi EJ, Chang YS, Bang BK . Association of Arterial Stiffness with the Decrease of Post-Dialysis Blood Pressure in Maintained Hemodialysis Patients. The Korean Journal of Neuphrol. 2008; 27: 102-109;
  • Shouman MG, Abdallah NI, Meguid Ak AE, Salama EEE. Bone mineral density markers in children with steroid sensitive idiopathic syndrome. International Journal of Acade. Vol. 2. No. 3. May 2010;
  • Silva HC, Pinheiro MM, Genaro PS, Castro CH, Monteiro CM, Fonseca FA, Szejnfeld VL. Higher prevalence of morphometric vertebral fractures in patients with recent coronary events independently of BMD measurements. Bone. 2013 Feb;52 (2):562-7
  • Skladal P, Jilkova Z, Svoboda I, Kolar V. Investigation of osteoprotegerin interactions with ligands and antibodies using piezoelectric biosensors. Biosens Bioelectron. 2005 Apr 15;20 (10):2027-34
  • Stavroulopoulos A, Porter CJ, Pointon K, Monaghan JM, Roe SD, Cassidy MJ. Evolution of coronary artery calcification in patients with chronic kidney disease Stages 3 and 4, with and without diabetes. Nephrol Dial Transplant. 2011 Jan 11;
  • Stejskal D, Bartek J, Pastorkova R, Ruzicka V, Oral I, Horalik D. Osteoprotegerin, RANK, RANKL. Biomed Pap Med Fac Univ Palack. 2001 Dec;145 (2):61-4
  • Stejskal D, Zurek M, Bartek J, Jedelsky L, Ruzicka V. Osteoprotegerin and bone density. Biomed Pap Med Fac Univ Palack. 2001 Dec;145 (2):75-6
  • Sultan A, Avignon A, Galtier F, Piot C, Mariano-Goulart D, Dupuy AM, Cristol JP. Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients. Diabetes Care. 2008 Mar;31 (3):593-5
  • Tibullo D, Giallongo C, La Cava P, Berretta S, Stagno F, Chiarenza A, Conticello C, Palumbo GA, Di Raimondo F. Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol. 2009 Apr;37 (4):461-8
  • Tousoulis D, Siasos G, Maniatis K, Oikonomou E, Kioufis S, Zaromitidou M, Paraskevopoulos T, Michalea S, Kollia C, Miliou A, Kokkou E, Papavassiliou AG, Stefanadis C. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol. 2013 Sep 1;167 (5):1924-8
  • Özden FO, Sakallioğlu EE, Demir E, Bilgici B, Tunçel ÖK, Gökosmanoğlu F, Atmaca A. Effect of bisphosphonate as an adjunct treatment for chronic periodontitis on gingival crevicuar fluid levels of nuclear factor-κB ligand (RANKL) and osteoprotegerin in postmenopausal osteoporosis. J Oral Sci. 2017;59(1):147-155. doi: 10.2334/josnusd.16-0241
  • Ulivieri FM, Marchelli D, Como G, Valente G, Messa P, Raimondi AR, Piodi LP. Increased osteoprotegerin in Italian haemodialysis patients. Osteoporos Int. 2006 Dec;17 (12):1822-3; author reply 1824
  • Ulivieri FM, Piodi LP, Marotta G, Marchelli D, Corradini C, Parravicini L, Verdoia C, Gerundini P. Usefulness of osteoprotegerin in assessing responses to neridronate treatment in Paget’s disease of bone. J Orthopaed Traumatol 7. 192–194 (2006);
  • Vanella L, Kim DH, Asprinio D, Peterson SJ, Barbagallo I, Vanella A, Goldstein D, Ikehara S, Kappas A, Abraham NG. HO-1 expression increases mesenchymal stem cell-derived osteoblasts but decreases adipocyte lineage. Bone. 2010 Jan;46 (1):236-43
  • Vezzani G, Quartesan S, Cancellara P, Camporesi E, Mangar D, Bernasek T, Dalvi P, Yang Z, Paoli A, Rizzato A, Bosco G. Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis patients. J Enzyme Inhib Med Chem. 2017 Dec;32(1):707-711. doi: 10.1080/14756366.2017.1302440.
References to Summary

References to Osteoprotegerin

  • Asanuma YF, Shimada Y, Kouzu N, Yokota K, Nakajima K, Sato K, Akiyama Y, Isozaki M, Mikami AS, Kobayashi H, Mimura T. Serum osteoprotegerin concentration is associated with carotid atherosclerotic plaque in patients with rheumatoid arthritis. Mod Rheumatol. 2012 May 15;
  • Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Medscape Womens Health. 2000 Mar;5 (2):5
  • Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonne JF, Cristol JP, Dupuy AM. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007 Nov;30 (11):2934-9
  • Bai P, Sun Y, Jin J, Hou J, Li R, Zhang Q, Wang Y. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respir Res. 2011;12:157
  • Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998 May 1;12 (9):1260-8
  • Feuerherm AJ, Borset M, Seidel C, Sundan A, Leistad L, Ostensen M, Faxvaag A. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol. 2001;30 (4):229-34
  • Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004 Jul;35 (7):1636-41
  • Gurban CV, Mederle O. The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis. Rom J Morphol Embryol. 2011;52 (3 Suppl):1113-9
  • Hofbauer LC. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol. 1999 Sep;141 (3):195-210
  • Kerschan-Schindl K, Mitterbauer M, Fureder W, Kudlacek S, Grampp S, Bieglmayer C, Fialka-Moser V, Pietschmann P, Kalhs P. Bone metabolism in patients more than five years after bone marrow transplantation. Bone Marrow Transplant. 2004 Sep;34 (6):491-6
  • Lien G, Ueland T, Godang K, Selvaag AM, Forre OT, Flato B. Serum levels of osteoprotegerin and receptor activator of nuclear factor -kappaB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study. Pediatr Rheumatol Online J. 2010;8:30
  • Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation. 2005 Jun 14;111 (23):3119-25
  • Morse LR, Nguyen HP, Jain N, Williams S, Tun CG, Battaglino RA, Stashenko P, Garshick E. Age and motor score predict osteoprotegerin level in chronic spinal cord injury. J Musculoskelet Neuronal Inter. 2008 Jan-Mar;8 (1):50-7
  • Nellemann B, Gormsen LC, Dollerup J, Schmitz O, Mogensen CE, Rasmussen LM, Nielsen S. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care. 2007 Dec;30 (12):3122-4
  • Roysland R, Bonaca MP, Omland T, Sabatine M, Murphy SA, Scirica BM, Bjerre M, Flyvbjerg A, Braunwald E, Morrow DA. Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart. 2012 May;98 (10):786-91
  • Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C, Capitani S, Zauli G. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol. 2006 Dec;169 (6):2236-44
  • Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein i
Related Products Docs